Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Santen Pharmaceutical Co ( (JP:4536) ) has shared an update.
Santen Pharmaceutical Co., Ltd. announced the cancellation of 19.8 million treasury shares, representing 5.8% of its outstanding shares, effective November 28, 2025. This strategic move is expected to impact the company’s share structure, reducing the total number of outstanding shares to approximately 322.3 million, which could potentially influence shareholder value and market perception.
The most recent analyst rating on (JP:4536) stock is a Hold with a Yen1688.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen is involved in the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries. The company is committed to enhancing the prevention, diagnosis, and treatment of eye diseases, aiming to create a future where people can experience ‘Happiness with Vision.’
Average Trading Volume: 1,518,848
Technical Sentiment Signal: Buy
Current Market Cap: Yen520.3B
For detailed information about 4536 stock, go to TipRanks’ Stock Analysis page.